AllSci News
Merck initiates tender offer for Terns Pharmaceuticals
Merck Expands Hematology Pipeline via USD 3.0 Billion Tender Offer for Terns Pharmaceuticals
Eli Lilly signs up new Tau aggregation inhibitor candidates from AC Immune with USD 12.5m upfront
Oral small molecule Tau aggregation inhibitors from AC Immune SA's (NASDAQ: ACIU) Morphomer platform are at the center of an amended license and...
Radiopharm picks Siemens Healthineers to support Phase III radioligand supply
Radiopharm Theranostics (ASX: RAD; Nasdaq: RADX), a Sydney-based clinical-stage radiopharmaceutical company, and Siemens Healthineers signed a clinical supply agreement under which Siemens…
Alloy Therapeutics and Biogen partner on AntiClastic ASO platform for multiple targets
Alloy Therapeutics Inc., a privately held biotechnology ecosystem company based in Boston, announced a collaboration and license agreement with Biogen Inc. (Nasdaq:…
Gilead Sciences expands ADC oncology pipeline with USD 5b acquisition of Tubulis
Gilead Sciences Expands ADC Oncology Pipeline with USD 5 Billion Acquisition of Tubulis
NextCure’s anti-CDH6 ADC receives FDA Fast Track designation for platinum-resistant ovarian cancer
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company headquartered in Beltsville, Maryland, announced receipt of US FDA Fast Track Designation for SIM0505,…
Halozyme to support Vertex on microparticle delivery for three undisclosed targets
Halozyme Therapeutics Inc., (Nasdaq: HALO) headquartered in California, and Vertex Pharmaceuticals have entered into an exclusive global collaboration and license agreement covering…
Sanofi's BsAb lunsekimig hits endpoints for asthma, CRSwNP, falls short in dermatitis
Sanofi (EURONEXT: SAN; NASDAQ: SNY) reported that lunsekimig, its bispecific Nanobody targeting both TSLP and IL-13, met primary and key secondary endpoints...
Weill Cornell Medicine receives USD 3.25m NIH award for AAV gene therapy Alzheimer's trial
Weill Cornell Medicine has received a USD 3.25 million UG3 award from the National Institute on Aging to advance an AAV-mediated gene therapy into Phase I...
Takeda exits co-development of Denali's dementia drug
DNL593, a progranulin replacement biologic engineered with Denali Therapeutics' (NASDAQ: DNLI) TransportVehicle technology, will advance under sole Denali...
Praxis reports early positive data for antisense drug elsunersen in SCN2A genetic epilepsy
Praxis Precision Medicines (Nasdaq: PRAX) reported positive Phase I/II data from the EMBRAVE Part A trial of elsunersen in pediatric SCN2A developmental...
Tenvie Therapeutics initiates Phase I trial of NLRP3 inhibitor in obesity
Tenvie Therapeutics, a Brisbane, California-based biotech, announced the dosing of the first subject in a Phase I/Ib clinical study of TNV262, a small...
Akari turns to WuXi XDC to support RNA splicing-targeting ADC toward Phase I
Akari Therapeutics (Nasdaq: AKTX), a biotech that operates out of Florida and the UK, announced a strategic partnership with WuXi XDC (HKEX:…
Alar's ketamine therapy meets safety goals in treatment-resistant depression Phase I
Alar Pharmaceuticals, a Taiwan-based clinical-stage company listed on the TPEx exchange, reported Phase I results for ALA-3000, a subcutaneous...
Apnimed preparing for sleep apnea drug approval with USD 150m debt, royalty deal
Cambridge, Massachusetts-based Apnimed, Inc. has secured up to USD 150 million in debt financing from HealthCare Royalty Partners to support commercial...
The AllSci Brief
Systematic R&D and deal news. Daily.